My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
  • Your browser version may not work well with NCBI's Web applications. More information here...

Results: 1 to 20 of 105

1.

Immunolocalization of RANKL is increased and OPG decreased during dietary magnesium deficiency in the rat.

Rude RK, Gruber HE, Wei LY, Frausto A.

Nutr Metab (Lond). 2005 Sep 14;2(1):24.PMID: 16162295 [PubMed]Related articlesFree article

2.

Skeletal and hormonal effects of magnesium deficiency.

Rude RK, Singer FR, Gruber HE.

J Am Coll Nutr. 2009 Apr;28(2):131-41.PMID: 19828898 [PubMed - in process]Related articles

3.

Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.

Yamamoto Y, Udagawa N, Matsuura S, Nakamichi Y, Horiuchi H, Hosoya A, Nakamura M, Ozawa H, Takaoka K, Penninger JM, Noguchi T, Takahashi N.

Endocrinology. 2006 Jul;147(7):3366-74. Epub 2006 Apr 20.PMID: 16627581 [PubMed - indexed for MEDLINE]Related articlesFree article

4.

Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.

Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH.

J Biol Chem. 2006 Feb 3;281(5):2414-29. Epub 2005 Oct 25.PMID: 16251181 [PubMed - indexed for MEDLINE]Related articlesFree article

5.

Alteration of bone cell function by RANKL and OPG in different in vitro models.

Lin JM, Callon KE, Lin CQ, Bava U, Zheng MH, Reid IR, Cornish J.

Eur J Clin Invest. 2007 May;37(5):407-15.PMID: 17461987 [PubMed - indexed for MEDLINE]Related articles

6.

CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.

Vega D, Maalouf NM, Sakhaee K.

J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21. Epub 2007 Sep 25. Review.PMID: 17895323 [PubMed - indexed for MEDLINE]Related articlesFree article

7.

Effect of low-level laser treatment after installation of dental titanium implant-immunohistochemical study of RANKL, RANK, OPG: an experimental study in rats.

Kim YD, Kim SS, Hwang DS, Kim SG, Kwon YH, Shin SH, Kim UK, Kim JR, Chung IK.

Lasers Surg Med. 2007 Jun;39(5):441-50.PMID: 17523169 [PubMed - indexed for MEDLINE]Related articles

8.

Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.

Roudier MP, Bain SD, Dougall WC.

Clin Exp Metastasis. 2006;23(3-4):167-75. Epub 2006 Aug 16.PMID: 16912914 [PubMed - indexed for MEDLINE]Related articles

9.

Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.

Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.

Biochem Biophys Res Commun. 2006 Aug 25;347(2):460-7. Epub 2006 Jun 30.PMID: 16828054 [PubMed - indexed for MEDLINE]Related articles

10.

Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.

Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati A, De Paola V, Valleggi F, Nuti R.

Bone. 2007 Feb;40(2):457-63. Epub 2006 Sep 18.PMID: 16979395 [PubMed - indexed for MEDLINE]Related articles

11.

RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.

Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM.

Rheumatology (Oxford). 2006 Sep;45(9):1068-76. Epub 2006 Feb 20.PMID: 16490750 [PubMed - indexed for MEDLINE]Related articlesFree article

12.

The RANKL/RANK/OPG pathway.

Boyce BF, Xing L.

Curr Osteoporos Rep. 2007 Sep;5(3):98-104.PMID: 17925190 [PubMed - indexed for MEDLINE]Related articles

13.

Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.

Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.

J Periodontal Res. 2006 Aug;41(4):354-60.PMID: 16827732 [PubMed - indexed for MEDLINE]Related articles

14.

Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Kananen K, Volin L, Laitinen K, Ruutu T, Välimäki MJ.

Osteoporos Int. 2006;17(5):724-30. Epub 2005 Dec 31.PMID: 16437190 [PubMed - indexed for MEDLINE]Related articles

15.

Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.

Shaarawy M, Fathy SA, Mehany NL, Hindy OW.

Clin Chem Lab Med. 2007;45(11):1498-503.PMID: 17970704 [PubMed - indexed for MEDLINE]Related articles

16.

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.

Stolina M, Dwyer D, Ominsky MS, Corbin T, Van G, Bolon B, Sarosi I, McCabe J, Zack DJ, Kostenuik P.

J Immunol. 2007 Dec 1;179(11):7497-505.PMID: 18025194 [PubMed - indexed for MEDLINE]Related articlesFree article

17.

Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.

Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.

Menopause. 2007 Sep-Oct;14(5):913-8.PMID: 17667143 [PubMed - indexed for MEDLINE]Related articles

18.

Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars.

Low E, Zoellner H, Kharbanda OP, Darendeliler MA.

Am J Orthod Dentofacial Orthop. 2005 Oct;128(4):497-503.PMID: 16214633 [PubMed - indexed for MEDLINE]Related articles

19.

Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.

Vitovski S, Phillips JS, Sayers J, Croucher PI.

J Biol Chem. 2007 Oct 26;282(43):31601-9. Epub 2007 Aug 15.PMID: 17702740 [PubMed - indexed for MEDLINE]Related articlesFree article

20.

The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.

Geusens PP, Landewé RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DM, van der Linden S, Boers M.

Arthritis Rheum. 2006 Jun;54(6):1772-7.PMID: 16736519 [PubMed - indexed for MEDLINE]Related articlesFree article

Supplemental Content

Filter your results:

Find related data

Recent activity